Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROLL trial
jRCT2091220345Phase 2Completed
- Sponsor
- National Cancer Center Hospital
- Start
- Apr 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in rare cancer, sponsored by National Cancer Center Hospital. Primary endpoint: Objective response rate (central review). Started Apr 2018; status: completed.
02
Drugs
03
Conditions
rare cancer
Beyond the preview
Go deeper on jRCT2091220345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2091220345.